Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | CBLB | Q13191 | 14/20 | 0.39 |
| ▸ | CCKAR | P32238 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | STK3 | Q13188 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20098618 | 0.92 | CBLB (0.46) | LRRK2CCKBRCBLBCCKARSTK3 | |
| SCHEMBL20098482 | 0.92 | CBLB (0.46) | LRRK2CCKBRCBLBCCKARSTK3 | |
| SCHEMBL20098124 | 0.89 | CCKBR (0.44) | LRRK2CCKBRCBLBCCKAR | |
| SCHEMBL20098252 | 0.89 | CCKBR (0.44) | LRRK2CCKBRCBLBCCKAR | |
| SCHEMBL21117273 | 0.89 | CCKAR (0.40) | CCKBRCBLBCCKAR | |
| SCHEMBL20098534 | 0.85 | CCKBR (0.43) | CCKBRCBLBCCKAR | |
| SCHEMBL21117137 | 0.84 | CBLB (0.42) | LRRK2CCKBRCBLBCCKAR | |
| SCHEMBL20098590 | 0.83 | CBLB (0.50) | LRRK2CCKBRCBLBCCKAR | |
| SCHEMBL20098480 | 0.83 | CBLB (0.43) | CCKBRCBLBCCKAR | |
| SCHEMBL21117277 | 0.83 | CBLB (0.45) | CCKBRCBLBCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | LRRK2 4367/4885CCKBR 509/4885CBLB 2850/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | LRRK2 2116/4885CCKBR 3869/4885CBLB 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.